All Comments by Edward Koo

  1. Gamma-secretase-like cleavages of Notch and beta APP are mutually exclusive in human cells.
  2. Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition.
  3. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease.
  4. Treatment with controlled-release lovastatin decreases serum concentrations of human beta-amyloid (A beta) peptide.
  5. APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques.
  6. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier.
  7. FAD mutations in presenilin-1 or amyloid precursor protein decrease the efficacy of a gamma-secretase inhibitor: evidence for direct involvement of PS1 in the gamma-secretase cleavage complex.
  8. Presenilin-1 P264L knock-in mutation: differential effects on abeta production, amyloid deposition, and neuronal vulnerability.
  9. Preimplantation diagnosis for early-onset Alzheimer disease caused by V717L mutation.
  10. Cortical inflammation in Alzheimer disease but not dementia with Lewy bodies.
  11. Augmented senile plaque load in aged female beta-amyloid precursor protein-transgenic mice.
  12. Head circumference and incident Alzheimer's disease: modification by apolipoprotein E.
  13. Molecular neuropathology of transgenic mouse models of Down syndrome.
  14. Familial Danish dementia: a novel form of cerebral amyloidosis associated with deposition of both amyloid-Dan and amyloid-beta.
  15. Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease.